Top Ten most popular articles on Pharmafile.com this week!
pharmafile | November 16, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Korea, NICE, Samsung, Theresa May, UK, brexit, politics, top 10
The Samsung scandal played a prominent role in this weeks’ top ten after the South Korean firm was delisted from the South Korean stock exchange over accounting violations. Equally Brexit chaos was central to this weeks’ news after a deal was revealed by Theresa May. The ongoing disruption has seen the resignation of a number of prominent players as backbench Brexiteer Jacob Rees Mogg called for a vote of no-confidence in Theresa May.
Our appointments section played a central role as well as pharma veterans Dave Tudor and Michael Boyd took on new roles. However this weeks’ top story covered NICE’s decision not to approve AstraZeneca’s cancer drug Olaparib on the basis that it is too expensive. Check out this weeks’ top ten at Pharmafile.com!
10. Samsung BioLogics delisted over accounting violations
South Korean firm Samsung BioLogics has been delisted from the South Korean stock exchange.
9. Eisai’s Lenvima wins over NICE in liver cancer in just three months
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now be used routinely on the NHS in England and Wales for the first-line treatment of untreated, advanced, unresectable hepatocellular carcinoma (HCC).
8. German health minister Jens Spahn calls for faster adoption of biosimilars
Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut cost of healthcare in Germany.
7. Samsung Biologics shares fall by 20% after Korean investigation
Shares in Korean firm Samsung BioLogics plummeted this week, falling by as much as 20% on Monday, after the South Korean Securities and Futures Commission (SFC) indicated that it will issue a ruling on the 14th of November over the company’s alleged violation of accounting rules.
6. Alabama’s biggest insurer will no longer cover OxyContin prescriptions
The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision has come in response to the thousands of overdose deaths, caused by the drug each year.
5. Gilead appoint Pfizer and AbbVie veteran as VP of governmental affairs
Gilead have appointed Pfizer and AbbVie veteran Michael Boyd as VP of government affairs and policy strategies.
4. GSK veteran Dave Tudor joins MMIC in Scotland
GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre (MMIC), a new manufacturing centre designed to increase the speed and cost effectiveness of the process through which medicines are brought to market.
The UK government’s request that pharmaceutical companies stockpile an additional six weeks’ worth of medicine, in preparation for a no-deal Brexit, is a waste of time and money, representatives for the Welsh pharmaceutical industry have said.
2. Phamaceutical trade lobby responds to Brexit deal
The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a 585 page draft withdrawal agreement has been agreed to by both the United Kingdom and the European Union.
1. NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer.
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
